The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
 
Yufan Liu
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Teresa Improta
Employment - AstraZeneca
 
Michelle Marcovitz
Employment - AstraZeneca; Incyte
Stock and Other Ownership Interests - Incyte
Other Relationship - CDER/FDA (I)
 
Kate DiPiazza
Employment - AstraZeneca
 
Mark C. Lanasa
Employment - AstraZeneca; Immunocore
Stock and Other Ownership Interests - AstraZeneca